vs

Side-by-side financial comparison of Carter Bankshares, Inc. (CARE) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Carter Bankshares, Inc. is the larger business by last-quarter revenue ($39.8M vs $37.2M, roughly 1.1× Organogenesis Holdings Inc.). On growth, Carter Bankshares, Inc. posted the faster year-over-year revenue change (15.4% vs -57.1%). Over the past eight quarters, Carter Bankshares, Inc.'s revenue compounded faster (9.1% CAGR vs -46.5%).

Carter Bankshares, Inc. is a U.S. regional bank holding company operating Carter Bank & Trust, a community-focused financial institution. It offers a full range of retail and commercial banking products including deposit accounts, personal and business loans, and wealth management services, primarily serving consumers and small business clients across Virginia and North Carolina.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CARE vs ORGO — Head-to-Head

Bigger by revenue
CARE
CARE
1.1× larger
CARE
$39.8M
$37.2M
ORGO
Growing faster (revenue YoY)
CARE
CARE
+72.5% gap
CARE
15.4%
-57.1%
ORGO
Faster 2-yr revenue CAGR
CARE
CARE
Annualised
CARE
9.1%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CARE
CARE
ORGO
ORGO
Revenue
$39.8M
$37.2M
Net Profit
Gross Margin
30.8%
Operating Margin
27.8%
-185.1%
Net Margin
Revenue YoY
15.4%
-57.1%
Net Profit YoY
EPS (diluted)
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CARE
CARE
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$39.8M
$225.6M
Q3 25
$39.1M
$150.9M
Q2 25
$37.3M
$101.0M
Q1 25
$37.0M
$86.7M
Q4 24
$34.5M
$126.7M
Q3 24
$34.2M
$115.2M
Q2 24
$33.6M
$130.2M
Net Profit
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
$43.7M
Q3 25
$5.4M
$21.6M
Q2 25
$8.5M
$-9.4M
Q1 25
$9.0M
$-18.8M
Q4 24
$7.7M
Q3 24
$5.6M
$12.3M
Q2 24
$4.8M
$-17.0M
Gross Margin
CARE
CARE
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
CARE
CARE
ORGO
ORGO
Q1 26
-185.1%
Q4 25
27.8%
28.1%
Q3 25
18.3%
13.7%
Q2 25
28.5%
-12.5%
Q1 25
30.1%
-30.9%
Q4 24
31.0%
8.1%
Q3 24
20.5%
5.4%
Q2 24
17.6%
-10.7%
Net Margin
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
19.4%
Q3 25
13.9%
14.3%
Q2 25
22.8%
-9.3%
Q1 25
24.2%
-21.7%
Q4 24
6.1%
Q3 24
16.4%
10.7%
Q2 24
14.3%
-13.1%
EPS (diluted)
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
$0.38
$0.31
Q3 25
$0.24
$0.11
Q2 25
$0.37
$-0.10
Q1 25
$0.39
$-0.17
Q4 24
$0.36
$0.05
Q3 24
$0.24
$0.09
Q2 24
$0.21
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CARE
CARE
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$419.7M
Total Assets
$4.9B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CARE
CARE
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
$419.7M
$300.1M
Q3 25
$412.8M
$255.1M
Q2 25
$405.6M
$233.2M
Q1 25
$401.8M
$242.9M
Q4 24
$384.3M
$262.9M
Q3 24
$386.8M
$278.5M
Q2 24
$364.4M
$263.5M
Total Assets
CARE
CARE
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$4.9B
$598.7M
Q3 25
$4.8B
$509.8M
Q2 25
$4.8B
$461.1M
Q1 25
$4.7B
$467.4M
Q4 24
$4.7B
$497.9M
Q3 24
$4.6B
$446.3M
Q2 24
$4.5B
$443.2M
Debt / Equity
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CARE
CARE
ORGO
ORGO
Operating Cash FlowLast quarter
$39.9M
Free Cash FlowOCF − Capex
$31.8M
FCF MarginFCF / Revenue
79.9%
Capex IntensityCapex / Revenue
20.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$54.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
$39.9M
$39.4M
Q3 25
$11.8M
$3.1M
Q2 25
$9.6M
$-32.9M
Q1 25
$6.4M
$-19.9M
Q4 24
$36.9M
$10.9M
Q3 24
$10.3M
$8.7M
Q2 24
$-2.5M
$4.7M
Free Cash Flow
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
$31.8M
$34.8M
Q3 25
$10.3M
$844.0K
Q2 25
$7.7M
$-36.5M
Q1 25
$4.9M
$-23.6M
Q4 24
$28.8M
$7.6M
Q3 24
$8.4M
$6.1M
Q2 24
$-4.3M
$2.9M
FCF Margin
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
79.9%
15.4%
Q3 25
26.3%
0.6%
Q2 25
20.6%
-36.1%
Q1 25
13.1%
-27.2%
Q4 24
83.5%
6.0%
Q3 24
24.6%
5.3%
Q2 24
-12.7%
2.2%
Capex Intensity
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
20.2%
2.1%
Q3 25
3.9%
1.5%
Q2 25
5.1%
3.6%
Q1 25
4.1%
4.2%
Q4 24
23.6%
2.7%
Q3 24
5.5%
2.2%
Q2 24
5.4%
1.4%
Cash Conversion
CARE
CARE
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
2.18×
0.14×
Q2 25
1.13×
Q1 25
0.71×
Q4 24
1.43×
Q3 24
1.83×
0.71×
Q2 24
-0.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons